News
11-08-2010, 04:10 AM
Lasofoxifene statistically reduced the overall risk of breast cancer, as well as ER positive invasive breast cancer in postmenopausal women with low bone density, according to a study published online in The Journal of the National Cancer Institute. Lasofoxifene is a SERM, or selective estrogen receptor modulator, that, like tamoxifen, blocks the effects of estrogen in breast tissue...
More... (http://mnt.to/f/3M9F)
More... (http://mnt.to/f/3M9F)